News
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...
AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback